DDInter1834 DDInter1140
Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines. It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults.[A188309,L10544,L43478] Since 2012, the extended-release formulation has been approved in combination with [phentermine] for chronic weight management therapy in adults. Characteristics that distinguish topiramate from other antiepileptic drugs are a monosaccharide chemical structure containing a sulfamate, and 40% of its mass accounted for by oxygen. Interestingly, topiramate was discovered by chance when attempts were made to formulate a novel antidiabetic drug.
Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 1963 until 1976. It was approved by the FDA in 1989, and was first marketed by Hoffman Laroche. This drug has been the subject of widespread controversy due to concerns regarding neurotoxic effects; product information warns of potential serious neuropsychiatric effects.[A226838,L8953]
Topiramate {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Mefloquine
Topiramate {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is downregulated by {v} (Compound) Mefloquine
Topiramate {u} (Compound) causes {v} (Side Effect) Loss of consciousness
Loss of consciousness {u} (Side Effect) is caused by {v} (Compound) Mefloquine
Topiramate {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Tetracycline
Tetracycline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mefloquine
Topiramate {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is regulated by {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Mefloquine
Topiramate {u} (Compound) causes {v} (Side Effect) Loss of consciousness
Loss of consciousness {u} (Side Effect) is caused by {v} (Compound) Flecainide
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Topiramate {u} (Compound) causes {v} (Side Effect) Influenza-like symptoms
Influenza-like symptoms {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mefloquine
Topiramate {u} (Compound) causes {v} (Side Effect) Cardiovascular disorder
Cardiovascular disorder {u} (Side Effect) is caused by {v} (Compound) Metoprolol
Metoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Topiramate {u} (Compound) causes {v} (Side Effect) Panic attack
Panic attack {u} (Side Effect) is caused by {v} (Compound) Bosentan
Bosentan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Topiramate {u} (Compound) binds {v} (Gene) SCN5A
SCN5A {u} (Gene) is bound by {v} (Compound) Flecainide
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Topiramate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mefloquine (Compound)
Topiramate (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Mefloquine (Compound)
Topiramate (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Mefloquine (Compound)
Topiramate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tetracycline (Compound) and Tetracycline may cause a minor interaction that can limit clinical effects when taken with Mefloquine
Topiramate (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is regulated by ABCB1 (Gene) and ABCB1 (Gene) is bound by Mefloquine (Compound)
Topiramate (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Flecainide (Compound) and Flecainide (Compound) resembles Mefloquine (Compound)
Topiramate (Compound) causes Influenza-like symptoms (Side Effect) and Influenza-like symptoms (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Mefloquine
Topiramate (Compound) causes Cardiovascular disorder (Side Effect) and Cardiovascular disorder (Side Effect) is caused by Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Topiramate (Compound) causes Panic attack (Side Effect) and Panic attack (Side Effect) is caused by Bosentan (Compound) and Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Topiramate (Compound) binds SCN5A (Gene) and SCN5A (Gene) is bound by Flecainide (Compound) and Flecainide (Compound) resembles Mefloquine (Compound)